CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in unprecedented rates of long-lasting complete responses in patients with leukemia and lymphoma. However, despite the impressive results in patients with hematologic malignancies, CAR-T cells have showed limited effe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02460/full |
| _version_ | 1818151771816591360 |
|---|---|
| author | Sonia Guedan Ramon Alemany |
| author_facet | Sonia Guedan Ramon Alemany |
| author_sort | Sonia Guedan |
| collection | DOAJ |
| description | Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in unprecedented rates of long-lasting complete responses in patients with leukemia and lymphoma. However, despite the impressive results in patients with hematologic malignancies, CAR-T cells have showed limited effect against solid cancers. New approaches will need to simultaneously overcome the multiple challenges that CAR-T cells encounter in solid tumors, including the immunosuppressive tumor microenvironment and heterogeneity of antigen expression. Oncolytic viruses are lytic and immunogenic anti-cancer agents with the potential to synergize with CAR-T cells for the treatment of solid tumors. In addition, viruses can be further modified to deliver therapeutic transgenes selectively to the tumor microenvironment, which could enhance the effector functions of tumor-specific T cells. This review summarizes the major limitations of CAR-T cells in solid tumors and discusses the potential role for oncolytic viruses as partners for CAR-T cells in the fight against cancer. |
| first_indexed | 2024-12-11T13:44:08Z |
| format | Article |
| id | doaj.art-c4d3959e5bc342c5930ad59215513c7d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T13:44:08Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c4d3959e5bc342c5930ad59215513c7d2022-12-22T01:04:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-10-01910.3389/fimmu.2018.02460417287CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor ChallengeSonia Guedan0Ramon Alemany1Department of Hematology and Oncology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainProCure Program, IDIBELL-Institut Catala d'Oncologia, L'Hospitalet de Llobregat, SpainAdoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in unprecedented rates of long-lasting complete responses in patients with leukemia and lymphoma. However, despite the impressive results in patients with hematologic malignancies, CAR-T cells have showed limited effect against solid cancers. New approaches will need to simultaneously overcome the multiple challenges that CAR-T cells encounter in solid tumors, including the immunosuppressive tumor microenvironment and heterogeneity of antigen expression. Oncolytic viruses are lytic and immunogenic anti-cancer agents with the potential to synergize with CAR-T cells for the treatment of solid tumors. In addition, viruses can be further modified to deliver therapeutic transgenes selectively to the tumor microenvironment, which could enhance the effector functions of tumor-specific T cells. This review summarizes the major limitations of CAR-T cells in solid tumors and discusses the potential role for oncolytic viruses as partners for CAR-T cells in the fight against cancer.https://www.frontiersin.org/article/10.3389/fimmu.2018.02460/fullchimeric antigen receptors (CAR)oncolytic virusessolid tumorsimmunotherapyimmunosuppressive tumor microenvironmentadoptive cell transfer (ACT) |
| spellingShingle | Sonia Guedan Ramon Alemany CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge Frontiers in Immunology chimeric antigen receptors (CAR) oncolytic viruses solid tumors immunotherapy immunosuppressive tumor microenvironment adoptive cell transfer (ACT) |
| title | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| title_full | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| title_fullStr | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| title_full_unstemmed | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| title_short | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| title_sort | car t cells and oncolytic viruses joining forces to overcome the solid tumor challenge |
| topic | chimeric antigen receptors (CAR) oncolytic viruses solid tumors immunotherapy immunosuppressive tumor microenvironment adoptive cell transfer (ACT) |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.02460/full |
| work_keys_str_mv | AT soniaguedan cartcellsandoncolyticvirusesjoiningforcestoovercomethesolidtumorchallenge AT ramonalemany cartcellsandoncolyticvirusesjoiningforcestoovercomethesolidtumorchallenge |